The cancer vaccine developed by MIT researchers has been able to appear very promising in the first phase of clinical trials. This vaccine can make it possible to treat cancers such as colon, pancreas and lung in the future.
According to Tekna technology and technology news service, researchers have been trying to make a cancer vaccine for years. It seems that now the researchers were able to achieve some successes in this field. MIT researchers succeeded in making a vaccine that has successfully achieved promising results in phase 1 clinical trials.
According to a report published in this case, a researcher named Darrel Irwin in the MIT research team founded an institute called Elicio Therapeutics in 2016, where efforts were made to develop and test a vaccine on humans to fight cancer. The current vaccine, ELI-002, is an albumin-based therapy that combines lipid-linked peptides with an immune conjugate, eliminating the need for CAR T cells.
In this institute, a clinical trial started in 2021 in which cancers with mutations in the gene were tested on people with pancreatic cancer. This type of cancer is aggressive and its treatment options are very limited. For this reason, dealing with it can bring important challenges. However, success in clinical trials and the simultaneous placement of seven types of genes involved in pancreatic cancer has been very promising. The results of the phase 1 clinical trial of this team in 2024 are very promising, and according to what was published in the journal Nature Medicine, it can be used in the development of a vaccine to treat this disease.
Latest Passing over countries : Spain | Dominica | United Arab Emirates
RCO NEWS
